Evaluation of Safety and Efficacy of RZL-012 for the Treatment of Lipedema or of Nodular Dercum's Disease
Status:
Completed
Trial end date:
2019-05-06
Target enrollment:
Participant gender:
Summary
Lipedema and Dercum's disease are known as Rare Adipose Disorders; they are painful,
progressive disorders that result in abnormal accumulations of fat in the form of lipomas,
excess lymphatic fluid, and many other symptoms. This trial aims to study RZL-012, a novel
compound, in treating lipedema and Dercum's disease by triggering lipolysis at selected sites
and reducing fat bringing pain relief and improvement in quality of life.